45 related articles for article (PubMed ID: 29543703)
1. Prognosis of CDKN2A germline mutation in patients with familial melanoma: a systematic review and meta-analysis.
Taibo A; Paradela S; Suanzes-Hernández J; Balboa-Barreiro V; Amado-Bouza J; Fonseca E
Melanoma Res; 2024 Feb; 34(1):9-15. PubMed ID: 37924530
[TBL] [Abstract][Full Text] [Related]
2. MELPREDICT: a logistic regression model to estimate CDKN2A carrier probability.
Niendorf KB; Goggins W; Yang G; Tsai KY; Shennan M; Bell DW; Sober AJ; Hogg D; Tsao H
J Med Genet; 2006 Jun; 43(6):501-6. PubMed ID: 16169933
[TBL] [Abstract][Full Text] [Related]
3. Genetic testing for familial melanoma.
Primiero CA; Maas EJ; Wallingford CK; Soyer HP; McInerney-Leo AM
Ital J Dermatol Venerol; 2024 Feb; 159(1):34-42. PubMed ID: 38287743
[TBL] [Abstract][Full Text] [Related]
4. Targeted sequencing analysis of loci implicated in familial melanoma in a Greek cohort.
Kypreou K; Stergiopoulou A; Plaka M; Befon A; Chardalia V; Stratigos IA; Stratigos AJ; Stefanaki I
J Eur Acad Dermatol Venereol; 2024 Jun; 38(6):e525-e527. PubMed ID: 38100224
[No Abstract] [Full Text] [Related]
5. Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer.
Hampel H; Pearlman R; Beightol M; Zhao W; Jones D; Frankel WL; Goodfellow PJ; Yilmaz A; Miller K; Bacher J; Jacobson A; Paskett E; Shields PG; Goldberg RM; de la Chapelle A; Shirts BH; Pritchard CC;
JAMA Oncol; 2018 Jun; 4(6):806-813. PubMed ID: 29596542
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer.
Colombo N; Huang G; Scambia G; Chalas E; Pignata S; Fiorica J; Van Le L; Ghamande S; González-Santiago S; Bover I; Graña Suárez B; Green A; Huot-Marchand P; Bourhis Y; Karve S; Blakeley C
J Clin Oncol; 2018 May; 36(13):1300-1307. PubMed ID: 29558274
[TBL] [Abstract][Full Text] [Related]
7. [CDKN2A gene in melanoma].
Liu MT; Liu JY; Su J
Zhonghua Bing Li Xue Za Zhi; 2019 Nov; 48(11):909-912. PubMed ID: 31775447
[TBL] [Abstract][Full Text] [Related]
8. A novel CDKN2A in-frame deletion associated with pancreatic cancer-melanoma syndrome.
Bottillo I; Valiante M; Menale L; Paiardini A; Papi L; Janson G; Sestini R; Iorio A; De Simone P; Frascione P; Grammatico P
Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941720
[TBL] [Abstract][Full Text] [Related]
9. An Unanticipated Modulation of Cyclin-Dependent Kinase Inhibitors: The Role of Long Non-Coding RNAs.
Bencivenga D; Stampone E; Vastante A; Barahmeh M; Della Ragione F; Borriello A
Cells; 2022 Apr; 11(8):. PubMed ID: 35456025
[TBL] [Abstract][Full Text] [Related]
10. Familial Melanoma and Susceptibility Genes: A Review of the Most Common Clinical and Dermoscopic Phenotypic Aspect, Associated Malignancies and Practical Tips for Management.
Zocchi L; Lontano A; Merli M; Dika E; Nagore E; Quaglino P; Puig S; Ribero S
J Clin Med; 2021 Aug; 10(16):. PubMed ID: 34442055
[TBL] [Abstract][Full Text] [Related]
11. A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhibition.
Horn IP; Marks DL; Koenig AN; Hogenson TL; Almada LL; Goldstein LE; Romecin Duran PA; Vera R; Vrabel AM; Cui G; Rabe KG; Bamlet WR; Mer G; Sicotte H; Zhang C; Li H; Petersen GM; Fernandez-Zapico ME
J Biol Chem; 2021; 296():100634. PubMed ID: 33823155
[TBL] [Abstract][Full Text] [Related]
12.
Tovar-Parra JD; Gutiérrez-Castañeda LD; Gil-Quiñones SR; Nova JA; Pulido L
Biomed Res Int; 2020; 2020():7458917. PubMed ID: 33102592
[TBL] [Abstract][Full Text] [Related]
13. P14
Cilluffo D; Barra V; Di Leonardo A
Genes (Basel); 2020 Jul; 11(7):. PubMed ID: 32698529
[TBL] [Abstract][Full Text] [Related]
14. CDKN2A germline alterations in melanoma patients with personal or familial history of pancreatic cancer.
De Unamuno B; García-Casado Z; Bañuls J; Requena C; Lopez-Guerrero JA; Nagore E
Melanoma Res; 2018 Jun; 28(3):246-249. PubMed ID: 29543703
[TBL] [Abstract][Full Text] [Related]
15. Cancer risks and survival in patients with multiple primary melanomas: Association with family history of melanoma and germline CDKN2A mutation status.
Helgadottir H; Tuominen R; Olsson H; Hansson J; Höiom V
J Am Acad Dermatol; 2017 Nov; 77(5):893-901. PubMed ID: 28818438
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome.
Lynch HT; Brand RE; Hogg D; Deters CA; Fusaro RM; Lynch JF; Liu L; Knezetic J; Lassam NJ; Goggins M; Kern S
Cancer; 2002 Jan; 94(1):84-96. PubMed ID: 11815963
[TBL] [Abstract][Full Text] [Related]
17. Surveillance of second-degree relatives from melanoma families with a CDKN2A germline mutation.
van der Rhee JI; Boonk SE; Putter H; Cannegieter SC; Flinterman LE; Hes FJ; de Snoo FA; Mooi WJ; Gruis NA; Vasen HF; Kukutsch NA; Bergman W
Cancer Epidemiol Biomarkers Prev; 2013 Oct; 22(10):1771-7. PubMed ID: 23897584
[TBL] [Abstract][Full Text] [Related]
18. CDKN2A mutations with p14 loss predisposing to multiple nerve sheath tumours, melanoma, dysplastic naevi and internal malignancies: a case series and review of the literature.
Sargen MR; Merrill SL; Chu EY; Nathanson KL
Br J Dermatol; 2016 Oct; 175(4):785-9. PubMed ID: 26876133
[TBL] [Abstract][Full Text] [Related]
19. Familial cutaneous melanoma.
Hansson J
Adv Exp Med Biol; 2010; 685():134-45. PubMed ID: 20687502
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
